January 21, 2026

Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies

​Novo Nordisk and Aspect Biosystems have started a new phase in their ongoing partnership focused on curative cellular medicines to...

January 20, 2026

Passwordless authentication at top of healthcare IT leaders’ priorities, report shows

​A new survey by security firm Imprivata has found that a majority of IT leaders in healthcare view ‘passwordless’ authentication...

January 20, 2026

Hospital cybersecurity: the threat in every HCP’s pocket

​The use of mobile devices in hospitals to streamline workflows and improve patient care has become commonplace. For cyber-attackers, this...

January 20, 2026

Guardant and MSD collaborate on companion diagnostics development

​Guardant Health has entered a multi-year strategic partnership agreement with Merck (MSD) for the development of companion diagnostics.The post Guardant...

January 20, 2026

Nxera reports positive outcomes for daridorexant Phase III insomnia study

​Nxera Pharma has announced positive top-line results from its Phase III study of daridorexant 50 mg, aimed at treating insomnia...

January 20, 2026

iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson’s

​iRegene Therapeutics has received RMAT designation from the US FDA for its lead product, NouvNeu001, aimed at treating PD.The post...

January 19, 2026

Zylox-Tonbridge to acquire German medical technology company Optimed

​Zylox-Tonbridge, a Hong Kong-listed company, has agreed to acquire German medical technology company Optimed.The post Zylox-Tonbridge to acquire German medical...

January 19, 2026

Genmab reports top line results in Phase III DLBCL trial

​Genmab has announced topline results from the Phase III EPCORE DLBCL-1 trial, highlighting improved PFS for its subcutaneous bispecific antibody,...

January 19, 2026

FDA grants Novartis’ ianalumab breakthrough therapy status for Sjögren’s disease

​Novartis has announced that the FDA has granted a breakthrough therapy designation to ianalumab, a treatment for Sjögren’s disease.The post...

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.